Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 9/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107503 | 0.91 | ALDH2 (0.54) | ADORA2BL3MBTL1POLBALDH2MAOA | |
| SCHEMBL2108076 | 0.90 | ALDH2 (0.44) | ALDH1A1ALDH2MAOAMAOBSPHK2 | |
| SCHEMBL2107891 | 0.90 | ADORA2B (0.49) | ADORA2BL3MBTL1POLBMAPTMAPK1 | |
| SCHEMBL4091603 | 0.90 | ADORA2B (0.51) | ADORA2BL3MBTL1POLBMAPTMAPK1 | |
| SCHEMBL4099655 | 0.87 | L3MBTL1 (0.49) | ADORA2BL3MBTL1POLBMAPTMAPK1 | |
| SCHEMBL2106845 | 0.87 | KIF11 (0.47) | ADORA2BL3MBTL1POLBMAPTMAPK1 | |
| SCHEMBL2106886 | 0.87 | ALDH2 (0.43) | MAPTALDH1A1ALDH2MAOAMAOB | |
| SCHEMBL2108380 | 0.87 | PPARG (0.42) | ADORA2BL3MBTL1POLBMAPTMAPK1 | |
| SCHEMBL2106711 | 0.86 | ALDH2 (0.54) | ALDH2MAOAMAOB | |
| SCHEMBL2108763 | 0.85 | ADORA2B (0.47) | ADORA2BL3MBTL1POLBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | claimed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | claimed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ADORA2B 2494/4885L3MBTL1 2793/4885POLB 2083/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ADORA2B 2559/4885L3MBTL1 2779/4885POLB 2249/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | ADORA2B 489/4885L3MBTL1 3461/4885POLB 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.